1ZP2MA, also known as [1-(indolizin-1-yl)propan-2-yl](methyl)amine or as 1-(indolizin-1-yl)-N-methylpropan-2-amine, is a monoamine releasing agent of the indolizinylethylamine family. It is the analogue and positional isomer of the stimulant-like drug α,N-dimethyltryptamine (α,N-DMT or N-methyl-α-methyltryptamine (N-methyl-αMT)) in which the indole ring has been replaced with an indolizine ring. 1ZP2MA has been found to be a potent dopamine releasing agent, with an of 62nM. It is the α-methyl and N-desmethyl analogue of (2-(indolizin-1-yl)ethyl)dimethylamine (TACT908; the indolizine analogue of dimethyltryptamine (DMT)). 1ZP2MA and 2ZEDMA were patented by Tactogen in 2023.
See also Indolizinylethylamine Substituted tryptamine § Related compounds 1Z2MAP1O α-Methylisotryptamine (isoAMT) BK-NM-AMT 3-APBT
References
External links 1ZP2MA - Isomer Design